Core Viewpoint - The Hang Seng Hong Kong Stock Connect Innovative Drug Index has seen a 0.3% increase, with significant gains in individual stocks, reflecting a positive trend in the innovative pharmaceutical sector driven by government policies and increasing demand for new drugs [1] Group 1: Market Performance - The Hang Seng Hong Kong Stock Connect Innovative Drug Index rose by 0.3% [1] - Notable stock performances include BGI Genomics rising over 7%, Tonghua Dongbao Pharmaceutical increasing over 4%, and Innovent Biologics up over 2% [1] - The trading volume for the Hong Kong Stock Connect Innovative Drug ETF, E Fund (159316), reached approximately 500 million yuan [1] Group 2: Government Policy - The "Guangzhou Plan for Accelerating the Construction of a Strong Advanced Manufacturing City (2024-2035)" was recently issued, emphasizing the acceleration of innovative drug strategic layout [1] - The plan focuses on the development of monoclonal antibodies, vaccines, blood products, and diagnostic reagents in the biopharmaceutical sector [1] - Other cities such as Beijing, Shanghai, Chongqing, and Xi'an have also introduced policies to promote high-quality development in the innovative drug industry [1] Group 3: Industry Outlook - Huachuang Securities believes that the pharmaceutical industry is reaching new heights due to the continuous demand for medical solutions and unmet needs [1] - Pharmaceutical companies are increasingly investing in research and development to meet these demands [1] - China has become a significant player in global innovative drug research and development, with a continuous rise in overseas licensing activity [1] - The industry is entering a revenue era driven by innovation [1] Group 4: Investment Opportunities - The Hang Seng Hong Kong Stock Connect Innovative Drug Index is the first index with a "purity" of 100% focused on innovative drugs, targeting leading companies in the Hong Kong stock market [1] - The E Fund (159316) is currently the only product tracking this index, providing investors with a streamlined way to capitalize on investment opportunities in this sector [1]
创新药概念午后拉升,关注港股通创新药ETF易方达(159316)布局机会
Mei Ri Jing Ji Xin Wen·2026-01-09 07:21